Angelini Ventures focuses its investments on cutting-edge startups in biotechnology and digital health, aiming to transform healthcare, improve patient outcomes, and address unmet needs, particularly in vulnerable populations. Their strategy involves investing globally in disruptive innovation across segments like Biotech, TechBio, Connected Health Devices, Digital Diagnostics & Therapeutics, and Hybrid Care Platforms, typically from Seed to Series A rounds.
55% of their portfolio is in Healthcare. Deal activity increased 150% year-over-year (5 deals in the last 12 months). Average disclosed round size is $43.7M (across 9 rounds with reported amounts).
Portfolio
11
Fund Size
$300M
Top Stage
Series C
Last 12 Mo
5
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
11 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Laigo Bio | Seed | $11.5M | Dec 2025 |
 CoMind | Series C | $60M | Oct 2025 |
 Adcytherix | Series A | $105M | Oct 2025 |
 Serenis | Series B | $12M | Oct 2025 |
 Elkedonia | Seed | $12.2M | Jun 2025 |
 Vantis Health | Series A | — | Mar 2025 |
 Nobi | Series B | — | Jan 2025 |
 Avation Medical | Series C | $22M | Feb 2024 |
| CCOUR Pharmaceuticals | Series A | $105M | Jan 2024 |
 Noctrix Health, Inc. | Series C | $40M | Jan 2024 |
 Cadence Neuroscience | Series B | $26M | May 2023 |
Top Co-Investors
Kurma Partners3 shared
Bpifrance2 shared
Plural1 shared
LocalGlobe1 shared
Octopus Ventures1 shared
Crane1 shared
Entrepreneur First1 shared
Latitude1 shared
Alpha Wave Global1 shared
Roche Venture Fund1 shared
Pfizer Ventures1 shared
Bristol Myers Squibb1 shared
Andera Partners1 shared
Surveyor Capital1 shared
aMoon1 shared
Pontifax1 shared
Dawn Biopharma1 shared
Pureos Bioventures1 shared
RA Capital Management1 shared
CDP Venture Capital1 shared
Last updated: 16 April 2026